Gene therapy shot could end monthly eye injections for wet AMD

NCT ID NCT04514653

Ongoing Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment is given as one or two injections into the eye and aims to produce proteins that block abnormal blood vessel growth, potentially replacing the need for frequent anti-VEGF injections. About 146 participants who have responded well to standard therapy will be randomly assigned to receive different doses of RGX-314 or the standard drug ranibizumab. The main goal is to see if RGX-314 can maintain or improve vision at 40 weeks compared to monthly ranibizumab injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

RGX-314 gene therapy (a one-time injection into the eye that produces anti-VEGF proteins)

What this could lead to

If successful, this could offer a one-time treatment for wet AMD, reducing or eliminating the need for frequent eye injections.

What could go wrong

This is a Phase 2 trial with a small number of participants. The gene therapy may not work as well as current injections, and there are risks like inflammation or infection from the procedure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)

Contacts and locations

Show contact details

Locations

California Retina Consultants - Bakersfield /ID# 255910

Bakersfield, California, 93309-1677, United States
California Retina Consultants - Santa Barbara /ID# 255923

Santa Barbara, California, 93103, United States
Charles Retina Institute /ID# 255922

Germantown, Tennessee, 38138, United States
Duke University Medical Center /ID# 267646

Durham, North Carolina, 27710, United States
Eye Associates of New Mexico /ID# 255915

Albuquerque, New Mexico, 87109, United States
Johns Hopkins Hospital /ID# 255919

Baltimore, Maryland, 21287, United States
Mid Atlantic Retina /ID# 255906

Philadelphia, Pennsylvania, 19107, United States
Northern California Retina Vitreous Associates Medical Group, Inc /ID# 255920

Mountain View, California, 94040-4101, United States
Ophthalmic Consultants of Boston /ID# 255917

Boston, Massachusetts, 02114, United States
Retina Consultants - The Woodlands /ID# 255924

The Woodlands, Texas, 77384, United States
Retina Consultants of San Diego /ID# 255911

Poway, California, 92064-2530, United States
Retina Vitreous Assoc Med Grp /ID# 255921

Beverly Hills, California, 90211, United States
Retinal Diagnostic Center /ID# 272275

Campbell, California, 95008, United States
Retinal Research Institute /ID# 255925

Phoenix, Arizona, 85053, United States
Sierra Eye Associates /ID# 255908

Reno, Nevada, 89502, United States
Southeast Retina Center /ID# 255912

Augusta, Georgia, 30909, United States
Springfield Clinic - First /ID# 272274

Springfield, Illinois, 62702, United States
Tennessee Retina - Nashville /ID# 255918

Nashville, Tennessee, 37203-1513, United States